Drug – bio-affecting and body treating compositions – Solid synthetic organic polymer as designated organic active... – Polymer from ethylenic monomers only
Patent
1984-04-27
1986-03-25
Rose, Shep K.
Drug, bio-affecting and body treating compositions
Solid synthetic organic polymer as designated organic active...
Polymer from ethylenic monomers only
424 19, 424 20, A61K 948, A61K 952
Patent
active
045782644
ABSTRACT:
This invention relates to a pharmaceutical dosage unit composition consisting essentially of a gelatin capsule containing (1) a disintegrating core comprising clonidine, said disintegrating core having a readily water-soluble coating, and (2) a plurality of non-disintegrating cores comprising clonidine, said non-disintegrating cores having a coating consisting of from 20 to 90 percent by weight of a water-insoluble film former and from 10 to 80 percent by weight of a water-soluble polymer, the diameter of each of the disintegrating and non-disintegrating cores being at least about 5 mm.
Arndts Dietrich
Bechtel Wolf D.
Bozler Gerhard
Brickl Rolf
Darda Siegfried
Boehringer Ingelheim GmbH
Rose Shep K.
LandOfFree
Retard form of pharmaceuticals with insoluble porous diffusion c does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Retard form of pharmaceuticals with insoluble porous diffusion c, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Retard form of pharmaceuticals with insoluble porous diffusion c will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-629914